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Mefloquine is a clinically useful anti-malarial compound active against strains of the 
Plasmodium parasite. The behavioral effects of each of the enantiomers of mefloquine were 
assessed. Clear quantitative differences were observed between the two enantiomers. The (+)-
(11R,12S)-enantiomer showed higher activity against Plasmodium falciparum. Another study 
revealed that the (-)-(11S,12R)-enantiomer specifically binds to adenosine A2A receptors more 
strongly than the (+)-(11R,12S)-enantiomer, in the central nervous system. Progress has been 
made toward the enantioselective synthesis of (+)-(11R,12S)-8-chloromefloquine analog. An 
enantiometically pure product was obtained by using hydrozirconation followed by a zinc-
palladium catalyzed Negishi cross-coupling reaction and a Sharpless dihydroxylation as key 
steps. 
 A series of mefloquine analogs have been developed to facilitate future structure-activity 
relationships and the development of new antimalaria agents. A recent study suggested an 
increase in the potency with electron-withdrawing groups at both the 2- and 8-positions of the 
quinoline ring. According to this concept, six new 8-position derivatives were synthesized via a 
palladium mediated coupling reaction. 
Enantioselective Synthesis of Mefloquine Analogs 
and their Derivatives 
Akira Nakamura, M.S. 
University of Pittsburgh, 2009
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1.0  INTRODUCTION 
Falciparum malaria is an infectious disease caused by Plasmodium falciparum, a protozoan 
parasite, transmitted by the female Anopheles mosquitoes. P. falciparum is one of the most 
dangerous infections and often leads to death unless diagnosed early. Approximately 300 million 
cases of falciparum malaria occur, and more than a million people, mainly children, die each 
year.
1
 This major public health problem is aggravated by the widespread resistance to one or 
more anti-malarial drug in the last three decades. The mechanisms by which the parasite is 
chemoresistant to antimalarials generally involve chromosomal mutations.
2
  
 Quinine was the first effective treatment for malaria caused by P. falciparum, appearing 
in chemotherapeutics in the 17th century. It remained the antimalarial drug of choice until the 
1940s when other drugs replaced it. Since then, many anti-malarial drugs were developed to 
protect U.S. troops from malaria, particularly during World War II. Chloroquine, primaquine, 
proguanil, amodiaquine, sulfadoxine and pyrimethamine were all developed during this time 
(Figure 1).
3
 Chloroquine is very cheap and, until recently, was very effective, which made it the 
antimalarial drug of choice for many years in most parts of the world. However, resistance of 
Plasmodium falciparum to chloroquine probably arises through the sequential accumulation of 
mutations and has spread recently from Asia to Africa, making the drug ineffective against the 
most dangerous Plasmodium strain. Predicting the emergence and spread of resistance to current 
 2 
antimalarials and newly introduced compounds is necessary for planning malaria control and 
instituting strategies.
4,5 
 
 
Figure 1. Classical anti-malaria drugs 
 
Mefloquine, a clinically useful anti-malarial compound which is chemically related to 
quinine and active against strains of the Plasmodium parasite, is a product of the US Army’s 
antimalarial research program. It was developed during the Vietnam War, in the beginning of the 
1970s, to protect American soldiers from the multi-drug resistant falciparum malaria, especially 
from chloroquine-resistant Plasmodium falciparum.
6
 Mefloquine has a high cure rate after a 
 3 
single dose of 250 mg, once a week, and is also efficient in preventing falciparum malaria when 
taken regularly. It is a very potent blood schizonticide with a long half-life. Its mechanism of 
action is thought to involve forming toxic heme complexes that damage parasitic food vacuoles.
7
 
However, resistance to mefloquine began to appear in Asia in 1985, around the time the drug 
became generally available. Nevertheless, mefloquine is still one of the most effective anti-
malarial therapies. 
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2.0  ENANTIOSELECTIVE SYNTHESIS OF MEFLOQUINE ANALOGS 
2.1 INTRODUCTION 
The pharmacological activities of each enantiomer of mefloquine were studied and clear 
quantitative differences were observed. Both of the pure mefloquine enantiomers were shown to 
be more effective against Plasmodium falciparumI than the racemic mixture, and, furthermore, 
the (+)-(11R,12S)-enantiomer showed the highest activity. In 1993, it was reported by Walter 
Reed Army Institute of Research (WRAIR) that (+)-(11R,12S)-enantiomer was 1.81 times more 
active than the (-)-enantiomer against chloroquine sensitive parasites (Sierra Leone D-6 clone) 
and also 1.69 times more active against chloroquine resistant (Indochina W-2 clone).
9
 The actual 
IC50 values were 34.4, 23.4 and 42.3 nM for racemic, (+)-enantiomer and (-)-enantiomer, 
respectively, against the D-6 clone, and 3.87, 4.09 and 6.61 nM against the W-2 clone. The 
WRAIR study concluded that the structure of the quinoline ring system containing the piperidine 
ring was important to differentiate the potency of each enantiomer because none of the 
enantiomers of acyclic analogs at the piperidine ring site nor any other aromatic system 
containing the piperidine ring displayed significant differences of activity among their respective 
enantiomers. Another study, reported in 2002, indicated a similar difference in activity between 
the two enantiomers against chloroquine resistant strains of Plasmodium flaciparum PF.IBS2, 
 5 
confirming that the (+)-(11R,12S)-mefloquine enantiomer was more potent than the (-)-
enantiomer (Figure 2).
10
 
 
Figure 2. In vitro activity of rac- and (±)-mefloquine against plasmodium falciparum PF.IBS2
10
 
 
The difference in side-effects for each enantiomer was also investigated. Remarkable 
differences of adverse effects between the two enantiomers were reported; for example, mice 
dosed with the (-)-enantiomer of mefloquine displayed clonic seizures, increased reactivity and 
reduced body weight after 48 h, though none of these effects were observed in mice treated with 
the (+)-enantiomer.
7
 The difference in psychotropic effects was explained by a specific binding 
of the (-)-enantiomer to adenosine A2A receptors in the central nervous system, with an affinity 
of 100 times that of the (+)-enantiomer.
11
 Nevertheless, exclusive racemic mefloquine is being 
sold under Roche’s trade name Lariam, maybe due to the lower cost and the convenience of the 
manufactural process for the racemic material. 
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2.2  CLASSIC AND RECENT MEFLOQUINE SYNTHESES 
As part of a search for superior anti-malarial drugs,-dialkylaminomethyl-4-quinolinemethanols 
were first synthesized in 1946 by Lutz et. al.
12
 Since the first synthesis of 2,8-
bis(trifluoromethyl)quinolin-4-yl-(2-piperidyl)methanol, mefloquine, was reported in 1971, 
several synthetic routes have been developed for the preparation of (±)-mefloquine.
13
 A popular 
method was, to first constract ketone 2 or the corresponding racemic alcohol, and then 
selectively reduce the pyridine ring to furnish (±)-mefloquine 1 (Scheme 1).
14
 Chiral resolution 
methods were developed by Carroll’s group for accessing enantiometically pure (+)-(11R,12S)-
mefloquine 1, and its absolute configuration was determined by comparison of CD spectra of the 
four optical isomers with the CD spectra of the stereoisomers of ephedrine and cinchona 
alkaloids in 1974.
15 
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Scheme 1. Racemic and asymmetric hydrogenation methods 
 
In 1993, the first asymmetric synthesis of (+)-(11R,12S)-mefloquine was reported by a 
Roche group using an enantioselective rhodium-catalyzed hydrogenation of -pyridyl ketone 2 
to give the -pyridyl alcohol 3 in moderate enantiomeric excess.16 Later, Schmid’s group 
achieved 92%ee by using a modified chiral catalyst and subsequent heterogeneous 
hydrogenation of the pyridine nucleus provided (11R,12S)-mefloquine 1 (Scheme 1).
17 
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Scheme 2. A recent asymmetric synthesis of (11R,12S)-mefloquine 
 
In 2008, the Zhi-Xiang group reported a new enantioselective synthesis of mefloquine 
using a proline-catalyzed aldol reaction and a Beckmann rearrangement as key steps (Scheme 
2).
18
 The synthesis started from the common intermediate 4-bromoquinoline 4. The 
corresponding aldehyde 5 was generated by halogen-metal exchange and formylation with DMF. 
The proline-catalyzed asymmetric direct aldol reaction provided a 6.8:1 ratio mixture of 
diastereomers 6. The enantiomeric purity of the desired syn-aldol 6 was checked by chiral HPLC 
analysis to be 74%ee. Treatment of 6 with hydroxylamine hydrochloride and sodium acetate 
gave oxime 7 in quantitative yield. A Beckmann rearrangement under standard conditions 
afforded the desired lactam 8. Finally, (11R,12S)-mefloquine 1 was obtained by the reduction of 
lactam 8 with borane-dimethyl sulfide complex. The high ee, 95%, was explained by a kinetic 
resolution through an amino alcohol-catalyzed enantioselective reduction of the lactam with 
borane.
19
 The overall yield of this synthesis was 14% over the 7 steps. 
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2.3 OUR APPROACH TO MEFLOQUINE ANALOGS 
 
Scheme 3. Retrosynthetic analysis of (11R,12S)-mefloquine analogs 9 
 
An enantioselective synthesis strategy of the target (11R,12S) 9 is illustrated in the retrosynthetic 
format in Scheme 3. Two stereocenters can be established from diol 11 via a cyclic sulfate 
opening, and the chiral diol 11 could be prepared by a Sharpless asymmetric dihydroxylation of a 
trans-olefin 12. Alkenylzirconocenes  have been useful intermediates since they are easily 
obtained by hydrozirconation reactions of alkynes.
20
 The olefin 12 would be obtained through 
further palladium-catalyzed cross-coupling reactions of the alkenylzirconocene and 4-
 10 
bromoquinoline 14.
21
 Each of the coupling components 13 and 14 can be prepared in 2 steps 
from commercially available compounds. 
 
2.4 RESULTS AND DISCUSSION 
The synthesis of intermediate 14 began with the PPA mediated condensation and subsequent 
cyclization of o-chloroaniline and ethyl 4,4,4-trifluoroacetoacetate to generate 15 in 60% yield 
(Table 1, entry 1).
22
 The reaction worked well on a 5 g scale; however, the yield decreased to 
30% on >10 g scale. Another quinolone synthesis method that was tested first formed the 
trifluoroacetoacetanilide intermediate in the presence of catalytic amounts of pTsOH under 
reflux conditions, followed by an in situ cyclization under vigorous conditions.
23
 Unfortunately, 
the yield did not increase significantly in spite of these attempted optimizations (Table 1, entry 2 
to 7). 
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Table 1. Synthesis of intermediate quinoline 15 
Entry Additive / Solvent Conditions Yield[%] 
1 
2 
3 
4 
5 
6 
7 
PPA 
pTsOH, PhH / Ph2O 
pTsOH, PhH / Ph2O 
pTsOH, PhH / Ph2O 
pTsOH, PhH / Ph2O 
pTsOH, Ph2O 
pTsOH, PhH / PhPh 
150 °C, 6 h 
100 °C, 8 h then 230 °C, 14 h 
100 °C, 8 h then 250 °C, 30 h 
100 °C, 8 h then 210 °C, 8 h 
100 °C, 8 h then 250 °C, 0.5 h
a
  
250 °C, 1 h
a
 
100 °C, 8 h then 210 °C, 14 h 
60 
34 
12 
43 
36 
30 
33 
a
 Irradiated in microwave. 
 
Quinolone 15 was then reacted with POBr3 at 150 °C, forming the corresponding 4-
bromo-8-chloro-2-trifluoromethylquinoline 14 in 95% yield. 
 
 
Scheme 4. Synthesis of intermediate 13 
 
Di-t-butyl iminodicarbonate was prepared by a literature procedure.
24
 Treatment of 
formamide with 2 equivalents of di-t-butyl dicarbonate in the presence of catalytic amounts (10 
mol%) of 4-dimethylaminopyridine (DMAP) generated di-Boc-formamide. Addition of 2-
 12 
diethylaminoethylamine (DEAEA) cleaved the formyl group to provide di-t-butyl 
iminodicarbonate. The 91% yield was better than the reported 80%. The Mitsunobu reaction of 
5-hexyl-1-ol and di-t-butyl iminodicarbonate with diisopropyl azodicarboxylate (DIAD) formed 
intermediate 13 in 69% yield.
25
 
Several conditions were explored for the cross-coupling reaction of fragments 16 and 14 
(table 2). First, alkenylzirconocene 16 was generated in situ by hydrozirconation of fragment 13 
with 1.1 equivalent of Schwartz’s reagent in THF at room temperature. In situ transmetalation 
with CuCl afforded the corresponding copper species. Subsequently, the cross-coupling was 
expected to proceed with bromoquinoline 14 in the presence of a catalytic amount of 
Pd(PPh3)4.
21
 however, target olefin 12 was not isolated and a quantitative amount of 
bromoquinoline 14 was recovered, even when the temperature was increased to reflux (Table 2, 
entry 1). The solvent system was found to be critical for the reaction and 30% of (E)-olefin 12 
was isolated when a 1:2 mixture of THF and NMP was used as a solvent (Table 2, entry 2). 
Alternative copper sources were also investigated, and copper(I) thiophene-2-carboxylate (CuTc) 
gave a slightly better 40% yield of olefin 12 (Table 2, entry 4). 
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Table 2. Zr/M/Pd coupling conditions for E-olefin 12 
Entry  Additive (1.1 eq) Solvent Temp. Time [h]  Yield of 12 [%] 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
 
 
 
 
 
 
 
 
 
 
 
CuCl 
CuCl 
CuCl 
CuTc 
ZnCl2 
ZnCl2 
ZnCl2 
ZnCl2 
ZnCl2 
ZnCl2 
ZnCl2 
THF 
1:2 THF/NMP 
1:2 THF/NMP 
1:2 THF/NMP 
THF 
1:2 THF/NMP 
1:2 THF/NMP 
1:2 THF/NMP 
1:2 THF/NMP 
1:1 THF/NMP 
2:1 THF/NMP 
rt to reflux 
rt 
0 
rt 
rt to reflux 
rt 
rt 
0 
50 
rt 
rt 
8 
14 
48 
24 
8 
14 
14 
48 
14 
14 
14 
 NR 
30 
NR 
40 
NR 
25 
NR 
NR 
NR 
50 
52 
 
In a similar protocol, Negishi reported the palladium catalyzed cross-coupling with 
alkenyizirconocenes via sequential transmetalation with ZnCl2.
26, 27
 THF turned out to be an 
 14 
ineffective solvent (Table 2, entry 5). However, 25% of the target (E)-olefin 12 was isolated in a 
1:2 ratio of the THF/NMP solvent system at room temperature (Table 2, entry 6). The reaction 
temperature was found to be equally important as the solvent system (Table 2, entries 7 to 9). 
Finally, 52% of (E)-olefin 12 were obtained by using a 2:1 ratio of THF/NMP at room 
temperature (Table 2, entry 11). 
 
 
Scheme 5. Synthesis of intermediate 12 by alkyne reduction 
 
Since the yield of the Zr/Cu/Pd or the Zr/Zn/Pd cross-coupling was not sufficient, another 
approach to form the (E)-olefin 12 was employed (Scheme 4). In 2005, Hayashi found a 
combination of hexamethyldisilane and deuterium oxide could be used as a deuterium transfer 
reagent for alkynes in the presence of a catalytic amount of a palladium complex to give (E)-
olefines predominantly.
28
 For example, they reported that a quantitative amount of stilbene was 
isolated in a >99:1 E/Z selectivity when diphenylacetylene was used as a starting material. 
 15 
Intermediate 17 was obtained in 89% yield via standard Sonogashira reaction of fragments 13 
and 14. Then, following a procedure by Hayashi, the formation of (E)-alkene 12 was expected to 
result from the isomerization of the corresponding (Z)-derivative. Unfortunately, the 
isomerization occurred only partly after 5 days under thermal conditions and resulted in a 2:1 
ratio mixture of (E/Z)-12 according to a 
1
H NMR analysis of the crude material. 
 
 
Scheme 6. Synthesis of intermediate 12 by Stille coupling 
 
Alternatively, a Stille coupling was also used to form 12 (Scheme 6).
 
Remarkably, when 
(E)-stannane 18, prepared in 84% yield from 13 by a standard protocol,
29
 was heated in NMP in 
the presence of catalytic amounts of Pd(PPh3)4 and CuI, a 3:1 ratio of E/Z mixture of olefin 12 
was isolated in 60% yield. Isomerization during Stille couplings is precedented but in most cases 
this effect is observed with tri-substituted alkenyl stannanes.
30, 31
 
In a similar fashion, a Suzuki coupling could be applied to form (E)-olefine 12. However, 
deprotection of the Boc-group occurred when intermediate 13 was treated with catecholborane in 
THF at room temperature. 
 16 
 
 
Scheme 7. Synthesis of (11R,12S)-8-chloro mefloquine analog 9 
 
The Sharpless asymmetric dihydroxylation of olefin 12 by AD-mix  proceeded very 
well to generated diol 11 in 90% yield and 99%ee based on chiral HPLC analysis comparing to 
the corresponding racemic diol.
32
 Diol 11 was treated with SOCl2 in the presence of excess 
pyridine to avoid the deprotection of the Boc-groups by the HCl generated in situ. The 
corresponding cyclic sulfite was formed quite cleanly, and the crude material was oxidized by a 
catalytic amount of RuCl3 at room temperature to give sulfate 10 in 85% yield over 2 steps.
33
 
Finally, the deprotection of 10 with TFA, followed by opening of the cyclic sulfate by the 
primary amine in the presence of Et3N formed the desired two stereocenters. Acidic hydrolysis 
with sulfuric acid generated the mefloquine analog 9 in 61% yield over 3 steps.
33
 To determine 
the enentiomeric excess, 9 was treated with isobutyraldehyde  in the presence of molecular 
 17 
sieves to generate 19. An ee of 99% was detected by SFC analysis in comparison to the 
corresponding racemic 19, prepared in the next chapter. 
2.5 CONCLUSION 
The enantioselective synthesis of the mefloquine analog 19 was achieved in 14% overall yield 
and 11 steps with excellet enantiomeric selectivity. The key step for generating the E-olefin 
intermediate was a Zr/Zn/Pd cross-coupling reaction. This process proceeded under mild 
conditions after optimization of the solvent system. Accordingly, this method may find general 
use in the synthesis of E-olefins from aryl halides. 
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3.0  LIBRARY SYNTHESIS OF MEFLOQUINE ANALOGS 
3.1 INTRODUCTION 
Currently, many anitimalarial drugs are available for therapy, but the rate of expansion of drug-
resistant malaria strains is likely to limit future treatment options. Mefloquine resistance has 
grown in South Asia as well as East Africa within the 6 years that mefloquine has been 
introduced as a treatment for regular falciparum induced malaria.
8
 Therefore, the development of 
next-generation mefloquine analogs is required to address the emerging resistance. 
From a screening program carried out at the WRAIR, an initial SAR for quinoline ring 
modified mefloquine analogs has emerged.
34
 These analogs have been used to analyze the three-
dimensional interaction between the drug and its target, which can facilitate the design of new 
antimalarial drugs. The study concluded that electronic features rather than steric factors were 
the primary effectors of antimalarial potency. Based on the results of a biological assay and a 
computational calculation, the group also proposed to increase the potency with electron-
withdrawing groups such as CF3- or phenyl or phenyl ether groups substituted by a halogen- or 
CF3- function at both the 2- and 8-positions of the quinoline ring. Various analogs with halogen, 
phenyl or functionalized arene groups at the 2-position were synthesized; replacement of CF3- by 
a 4-CF3-benzene group increased antimalarial activity by about 20%. 
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Table 3. Antimalarial activity of C8-mefloquine analogs
34
 
               Compound               Activity
a
 
Mefloquine 
WR228974 
WR117107 
WR073879 
X = -CF3 
X = -Cl 
X = -F 
X = -CH3 
1 
0.03 
NC
b
 
NC 
a
 The in vivo activity of the test compound is expressed in terms of the molar ratio of the 50% curative dose of 
mefloquine hydrochloride to that of the test compound. 
b 
Not curative. 
 
So far, only three C8-mefloquine analogs were synthesized and tested for biological 
activity (Table 3). The purpose of this project is to recognize a trend toward improved 
antimalarial potency by building a library of 8-position analogs of mefloquine. The result of 
these biological studies would provide further information about the steric environment, 
lipophilicity, electronic properties and hydrogen bonding donating and accepting effects, that are 
crucial to achieve antimalarial efficacy. 
3.2 SYNTHETIC STRATEGY 
Aryl bromides have been of interest for chemists as precursors of other functionalized arenes, 
providing an entry point to a wide variety of compounds through metal-catalyzed couplings 
reactions or other substitution processes. Because of their moderate accessibility and reactivity, 
 20 
these building blocks have been commonly used in medicinal chemistry as starting materials for 
library synthesis.
35
 In contrast, aryl chlorides have generally been considered to be unreactive for 
metal-catalyzed cross-coupling reactions, but the recent development of new catalysts has 
allowed an expansion of their utility as synthetic intermediates. Indeed, these systems have been 
used in Stille
36
 or Suzuki reactions
37
 using palladium catalysis and in cross-coupling reactions 
with Grignard
38
 or organozinc reagents
39
 using nickel catalysis. Thus, the synthetic approach to 
C8-analogs involved the use of this new aryl chloride chemistry (Scheme 8). 
 
 
Scheme 8. Synthetic approach to C8-analogs 
  
3.3 RESULT AND DISCUSSION 
3.3.1 Racemic synthesis of 9 
As shown in chapter 2, the enantioselective synthesis was accomplished but was not sufficiently 
scalable, and therefore the classical racemic synthesis, reported by Lutz, was chosen to prepare 
intermediate 9 on scale.
14
 Intermediate 20 was obtained in 87% yield; first, the corresponding 
Grignard reagent was generated by treating 14 with 1.5 equivalent of iso-propyl magnesium 
 21 
chloride and then the reagent was quenched with 2-pyridinecarboxaldehyde (Scheme 9). 
Hydrogenation of 20 in the presence of a Brønsted acid and a catalytic amount of platinum oxide 
gave mefloquine analog 9. However, the product was found to be a 5:1 mixture of diastereomer 
according to 
1
H NMR analysis. A clearly related 5.7:1 ratio of diastereomers was obtained in 
quantitative yield when naphthylpyridyl alcohol was hydrogenated with platinum oxide at room 
temperature.
40
 Several solvents were tested for recrystallization, and finally a 60% yield of a 20:1 
ratio diastereomers of rac-9 was obtained on gram scale by recrystallization using MeOH. 
 
 
Scheme 9. Classical racemic synthesis of intermediate rac-9 
 
3.3.2 Kumada coupling 
In 2002, the Beller group developed a novel method for the palladium-catalyzed cross-coupling 
of alkyl chlorides and Grignard reagents which provided good to excellent yields at room 
temperature.
41
 As a result of the high reactivity of the palladium catalyst system, we explored the 
Kumada coupling for the coupling of intermediate rac-9 (Scheme 10). 
 22 
 
Scheme 10. Initial attempt of applying the Kumada coupling 
 
Initial attempts aimed to react rac-9 and a THF solution of phenyl magnesium bromide in 
the presence of catalytic amounts of Pd(OAc)2 and PCy3 in NMP; however, the starting material 
was recovered even after increasing the reaction temperature and also the amounts of Grignard 
reagent, Pd(OAc)2 and PCy3. The failure of this reaction can be potentially attributed to the 
chelate effect between the amino alcohol and the palladium catalyst. When the coordination sites 
of mefloquine were studied, a strongly chelating site was detected and the structure of the N,O-
chelate complex of mefloquine with palladium(II) was determined by X-ray diffraction 
analysis.
42
 
 
 
Scheme 11. Application of Kumada coupling reaction to form C8 analogs 
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In contrast to the results obtained for the Kumada coupling reaction of rac-9, coupling 
products 21 and 22 were isolated 78% and 71% yield, respectively, by reaction with 2.5 
equivalents of Grignard reagent. The preparation of the Grignard reagents followed a genereal 
protocol; The alkyl or aryl bromide and magnesium turnings were heated at reflux in THF for 1 h 
under the inert condition. The concentration of these reagents was determined by a titration 
technique using salicylaldehyde phenylhydrazone as an indicater.
43
 The hydrogenation of 
coupling products 21 and 22 generated the corresponding C8-mefloquine analogs rac-23 and 
rac-24 in 50% and 79% yield (Scheme 11). 
 
 
Scheme 12. Formation of the oxazolidine 
 
Another approach was also investigated to overcome the chelating problem by installing 
an oxazolidine. The oxazolidine ring could easily be prepared by the reaction of 2,2-
dimethoxypropane (DMP) and rac-9 in the presence of a catalytic amount of p-toluenesulfonic 
acid (pTsOH).
44
 Unfortunately, the pure oxazolidine was not obtained after a simple work-up 
and decomposition was observed during the purification by chromatography on silica gel. On the 
other hand, the desired oxazolidine rac-19 was isolated in 89% yield by treatment of rac-9 with 
an excess of isobutyraldehyde in the presence of 4Å MS at room temperature (Scheme 12).
45
 It is 
 24 
interesting to note that the oxazolidine rac-19 was formed as a single diastereomer according to 
the 
1
H NMR. 
 
 
Table 4. Deprotection conditions of oxazolidine rac-25 
Entry  Additive Solvent Temp. Time  Result
a
 
1 
2 
3 
4 
5 
 
 
 
 
 
pTsOH 
HCl 
FeCl3-SiO2   
HCl, 1,3-propanedithiol 
  pTsOH, neopentylglycol 
MeOH 
MeOH 
CHCl3 
CF3CH2OH 
MeOH 
rt 
rt 
rt 
rt 
rt  
3 d 
3 d 
1 d 
12 h 
18 h 
 NR 
NR 
NR 
quant. 
quant. 
a
 Based on TLC analysis. 
 
As mentioned previously, Kumada couplings were successfully performed in the absence 
of the amino alcohol group (Scheme 10). The purification by chromatography was found to be 
very difficult because of the similar polarity of the starting material rac-19 and the coupling 
product rac-25, even though the coupling products were easily observed in the crude 
1
H NMR 
and TLC analyses. Therefore, the seemingly straightforward deprotection was applied without 
further purification, but the conventional protocols were unsuccessful (Table 5, entry 1 and 
2).
46,47
 The FeCl3-SiO2 reagent has been well established for the cleavage of acetals in 
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chloroform at room temperature.
48
 The reaction was supposed to be finished in a couple of hours, 
but most of the starting material was recovered after 1 day (Table 5, entry 3). In contrast, Corey’s 
protocol using HCl and 1,3-propanedithiol in trifluoroethanol as a solvent, worked well at room 
temperature (Table 5, entry 4).
49
 Finally, the deprotection was successful in a mixture of pTsOH 
and neopentylglycol (2,2-dimethyl-1,3-propanediol) in methanol (Table 5, entry 5), and provided 
the desired C8 analog rac-22 in quantitative yield. 
 
3.3.3 Phenol synthesis from arylchoride 
Phenols are widespread in nature and are common products in synthetic chemistry. Aryl halides 
would be suitable precursors to phenols but, generally, reactions that convert aryl halides to 
phenols in the absence of a catalyst require strongly basic conditions, high temperatures, and 
elevated pressures.
50
 In 2006, Buchward reported a palladium-catalyzed formation of C-O bonds 
was an effective method for the construction of phenols from aryl halides in the presence of 
bulky, monodentate phosphine ligands.
51
 Intermediate rac-19 was treated with KOH in the 
presence of a catalytic amount of Pd2dba3 and tert-butyl X-phos ligand 26 in a mixture of 
degassed water and 1,4-dioxane (Scheme 12); however, no desired phenol was isolated even 
though all starting material rac-19 was consumed, implying that the oxazolidine ring was not 
significantly stable to relatively strong base under thermal conditions. 
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Scheme 13. Initial attempt at phenol synthesis from rac-19 
 
 In contrast, the Buchward protocol worked well using intermediate 20 under slightly 
harsher conditions. Conversion was accomplished in the microwave at 120 °C after only 30 min 
to afford the corresponding phenol 27 in 56% yield (Scheme 14). Subsequently, the 
hydrogenation with PtO2 furnished the C8-hydroxy analog rac-28 in 38% yield after 
recrystalization. At this stage, the C8-methoxy analog was considered to be easily accessible 
from the corresponding intermediate 29 which was obtained in 90% yield by selective 
methylation of phenol 27; however, the hydrogenation of 29 always gave messy products. An 
overreduction of the quinoline ring was reported as the absence of C2-CF3- substitution 
decreased the selectivity of the protonation of the pyridine vs the quinoline ring.
13
 The absence 
of selectively in the presence of the methoxy group on the quinoline ring is reflective of the 
increase of electron density in the quinoline, which leads to diminished steric interactions and a 
redistribution of electronic effects. 
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Scheme 14. Synthesis of C8-O mefloquine derivatives 
 
 
Scheme 15. Synthesis of the C8-methoxy analog rac-30 
 
The synthetic strategy was slightly modified to first prepare oxazolidine rac-31 from 
phenol rac-28 (Scheme 15). Oxazolidine rac-31 was sufficiently pure after a simple work-up and 
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could be used in the next reaction without any purification. Methylation and deprotection 
provided a quantitative yield of the desired C8-methoxy analog rac-30. 
 
3.3.4 Nitrile synthesis 
Aryl nitriles represent important ingredients for the preparation of dyes, pesticides, 
agrochemicals, medicines, and bioactive natural products. A variety of synthetic methods for the 
preparation of aryl nitriles have been developed. The most direct method is the metal catalyzed 
cyanation of aryl halides.
52
 Another well-known protocol is the Rosenmund-von Braun reaction; 
an aryl halide reacts with copper cyanide to give an aryl nitrile. However, these reactions require 
relatively high temperatures of up to 150–250 °C, which is incompatible with sensitive substrates. 
The process is also limited to aryl bromides and iodides. Several metal-catalyzed cross-coupling 
reactions have been reported, but these methodologies were not applicable for aryl chlorides due 
to the low reactivity of sp
2
-carbon linked
 
chlorides.
53
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Table 5. Conditions for nitrile coupling 
Entry  Ligand Solvent Temp.[°C] Time [min]  Yield of 
rac-19 [%] 
1 
2 
3 
4 
5 
6 
 
 
 
 
 
 
dppf 
S-phos 
S-phos 
S-phos 
S-phos 
S-phos 
DMF 
NMP 
NMP 
NMP 
NMP 
NMP 
 160
a
 
 160
a
 
 140
a
 
 130
a
 
130 
110  
30 
30 
30 
30 
60 
60 
  0
b
 
 0
b
 
25 
.47 
38 
0
c
 
a
 Irradiated in microwave. 
b
 rac-19 was consumed but no rac-32 was isolated. 
c 
rac-19 was recovered. 
 
In 2000, the first successful palladium catalyzed cyanation coupling of aryl chlorides was 
published by the DuPont Company.
54
 Following the reported protocol, intermediate rac-19 was 
treated with 0.6 equivalent of zinc cyanide in the presence of a catalytic amount of Pd2dba3 and 
1,1'-bis(diphenylphosphino)ferrocene (dppf) in DMF at 160 °C under microwave conditions for 
30 min (Table 5, entry 1). The reaction was repeated twice, but no target cyanide rac-32 was 
isolated. An alternative, more efficient protocol was reported by the Merck Company in 2006.
55
 
They found that the 2-(2’,6’-dimethoxybiphenl-yl)dicyclohexylphosphine (S-phos) ligand was a 
more effective promoter of the cyanation of aryl chlorides than dppf or 1,5-
bis(diphenylphosphino)pentane (dpppe) under either microwave-assisted or thermal conditions. 
However, only a baseline spot was found by TLC analysis of a reaction performed at 160 °C 
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under microwave conditions (Table 5, entry 2). In contrast, 25% of nitrile rac-32 was isolated 
under milder conditions (Table 5, entry 3). Finally, nitrile rac-32 was prepared in 47% yield by 
heating a reaction mixture at 130 °C for 30 min in the microwave (Table 5, entry 4). The 
coupling also proceeded under thermal conditions, but the resulting yield was lower (Table 5, 
entry 5). The deprotection of nitrile rac-32 gave the C-8 nitrile analog rac-33 in 78% yield. 
 
 
Scheme 16. Hydrolysis of  nitrile rac-33 
 
Acid- or base-catalyzed hydration of a nitrile is a method frequently used for the 
preparation of the corresponding carboxylic acids or esters, occurring in two steps through an 
intermediate amide. The selective hydrolysis of a nitrile to an amide is difficult to achieve, 
because the amide is often more easily hydroyzed than the nitrile.
57
 Classical methods for the 
nitrile hydrolysis were applied to rac-33,
56, 58 
however, two of these general methods resulted in 
messy reaction mixture (Scheme 16). 
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Scheme 17. Synthesis of C8-amide rac-36 
 
The conversion of nitriles to the corresponding primary amides can also be performed 
with hydrogen peroxide under basic conditions.
57
 Actually, this reaction proceeded very well for 
nitrile rac-32 at 50 °C, even though no reaction occurred at room temperature, and the primary 
amide rac-35 was isolated in 92% yield. The deprotection of rac-35 afforded the C8-primary 
amide analog rac-36 in 94% yield. Further attempts to generate the C8-carboxy acid or ester 
failed. 
3.3.5 Negishi coupling 
In an attempt to synthesize C8-benzyl analogs, the Kumada coupling protocol was applied to 
intermediate rac-19 using commercially available benzyl magnesium chloride at room 
temperature or 50 °C, but no reaction was observed (Scheme 18). The stability of benzyl 
magnesium chloride in NMP could be the problem with this process. In 2005, the Gosmini group 
reported a method for the preparation of an aryl zinc species from the corresponding aromatic 
chlorides in a mixture of acetonitrile and pyridine, using cobalt catalysis. A subsequent Negishi 
reaction allowed the preparation of the desired coupling product in modest yield.
59
 Intermediate 
rac-19 was treated with commercially available zinc dust activated by traces of TFA in the 
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presence of CoBr2 (0.33 equiv) in acetonitrile–pyridine at room temperature. The resulting 
organozinc species was quenched with benzaldehyde or applied to the Negishi coupling with 
benzyl bromide. Unfortunately, in both cases, the corresponding rac-38 was isolated as the major 
product. Most likely, the stability of the organozinc intermediate 37 is inefficient in these 
reactions. 
 
 
Scheme 18. Attempt toward the synthesis of a C8-benzyl analog 
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3.4 SELECTIVE COUPLING OF BIS-CHLOROQUINOLINE SYSTEM  
3.4.1 Regioselectivity of quinoline 
Bis- and trichloromefloquine analogs of WR226253 and WR007936 have curative antimalarial 
activity in vivo, showing lower IC50’s for several P. flaciparum strains and lower neurotoxicity 
than mefloquine (Figure 3).
60
 It is therefore worthwhile to develop analogs for next-generation 
anti-malarial drugs. 
 
 
Figure 3. Bis-chloro and trichloromefloquine analogs 
 
The regioselective preparation of bis-halo-quinolines is of great interest since they are 
useful starting materials for a number of polyfunctionalized quinolines. Therefore, the 
regioselective synthesis of these compounds can be valuable for the development of 
multifunctionalized quinoline derivatives. Some precedence has been reported regarding the 
regioselectivities of C2 versus C4 or C4 versus C8 sites of dihaloquinolines.
61 
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Scheme 19. Regioselective metalation of tribromoquinoline 
 
In 2008, the regioselective metalation of 4,6,8-tribromoquinoline was demonstrated via a 
lithium–halogen exchange reaction.61 Treatment of 4,6,8-tribromoquinoline with 2 equivalents of 
n-BuLi followed by quenching with electrophiles, water, trimethylsilyl chloride (TMSCl), or 
dimethyl disulphide (Me2S2), proceeded regioselectively at C4 and C8 sites and afforded the 
corresponding 4,8-disubstituted-6-bromoquinolines (Scheme 19). 
3.4.2 Selective Kumada coupling 
Following the procedure developed previously for the Kumada coupling of aryl chlorides, the 
regioselectivity of the bischloroquinoline 42 was explored as a test substrate. When 2.5 
equivalents of PhMgBr were used, the crude 
1
H NMR showed a 1:3 ratio of mono-coupling 
product 43 and bis-coupling product 44 (Table 6, entry 1). Several conditions were tested but the 
products were mixtures of mono- and bis-coupled quinolines (Table 6, entry 2 to 4). According 
to these results, a secondary cross-coupling reaction could be applied before consumption of the 
starting materials at room temperature. Fortunately, the differential reactivity of starting material 
42 and mono-coupling product 43 was apparent when the reaction was performed at 0 °C (Table 
6, entry 6). Finally, only the mono-coupling product 43 was generated when the reaction was 
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quenched after 4 h (Table 6, entry 7). However, because of the similar polarities, the product and 
starting material could not be well separated. 
 
 
Table 6. Conditions for selective Kumada coupling 
Entry  Additive Temp. Tiem[h]               Result
a
 
    42          43         44 
1 
2 
3 
4 
5 
6 
7 
 
 
 
 
 
 
 
2.5 eq PhMgBr 
1.2 eq PhMgBr 
2.0 eq PhMgBr 
2.0 eq PhMgBr 
4.0 eq PhMgBr 
2.5 eq PhMgBr 
2.5 eq PhMgBr 
rt 
rt 
rt 
rt 
rt 
0 °C 
0 °C 
24 
24 
24 
12 
3 
6 
4 
0 
4 
2 
3 
0 
1 
2 
1 
2 
1 
2 
0 
4 
3 
3 
1 
1 
1 
 1
b
 
1 
0 
a
 Relative ratio of coupling  products 43, 44 and starting material 42 were determined by 
1
H NMR of the crude 
mixture. 
b
 Only isolated 44 in 83% yield. 
  
 The optimized conditions found above were applied to bischloro-mefloquine precursor 42, 
and a 47% yield of the mono-coupling product 43 was achieved (Scheme 20). The coupling site 
was determined by NOESY analysis, showing couplings both C6 and C8 protons on quinoline 
ring with ortho-protons on the benzene ring. 
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Scheme 20. Regioselective Kumada coupling 
3.4.3 Selective phenol synthesis 
 
Table 7. Conditions for selective phenol synthesis 
Entry  Additive Temp.[°C]
a
 Time [h]               Result
c
 
    42          47         48 
1 
2 
3 
4 
5 
6 
 
 
 
 
 
 
1.5 eq KOH 
3.0 eq KOH 
1.0 eq KOH 
1.2 eq KOH 
1.5 eq KOH 
1.4 eq KOH 
 100
b
 
150 
120 
120 
120 
120 
30 
0.5 
0.5 
0.5 
0.5 
0.5 
1 
0 
1 
1 
0 
0 
1 
0 
1 
2 
5 
 1
e
 
0 
 1
d
 
0 
0 
2 
0 
a 
Irradiated in microwave. 
b
 heated in an oil bath. 
c
 Relative ratio of coupling  products 47, 48 and starting material 
42 was determined by 
1
H NMR of the crude mixture. 
d
 Only isolated 48 in 68% yield. 
e
 Only isolated 47 in 80% 
yield. 
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The regioselectivity of the phenol synthesis that was previously used was also investigated 
(Table 7). Initially, reflux conditions were tested because the regioselectivity under thermal 
conditions might be superior to microwave irradiation (Table 7, entry 1). After 30 h, a 1:1 ratio 
of starting material 42 and mono-hydroxy quinoline 47 was isolated. Under microwave 
conditions, the dihydroxy quinoline 48 was predominantly generated in the presence of an excess 
amount of KOH (Table 9, entry 2), and a 1:1 ratio of starting material 39 and mono-hydroxy 
quinoline 48 was observed with 1 equivalent of KOH (Table 7, entry 3). The best selectivity was 
found at 120 °C under microwave conditions with 1.4 equivalents of KOH providing 80% of the 
mono-hydroxy quinoline 47. 
 
Scheme 21. Regioselective phenol synthesis 
 
These successfully optimized conditions were applied to the bischloromefloquine 
precursor 45 as well (Scheme 21). Even though the yield was decreased compared to the test 
reaction, 42% of C8 hydroxy 49 was isolated. The NOESY spectrum of the corresponding 
methoxy 50, prepared in 95% yield from 49, confirmed the site of the palladium-catalyzed 
phenol synthesis: the methoxy proton is only correlated with the C7 hydrogen and significant 
correlation is also observed between the C5 hydrogen and the benzyl hydrogen. 
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3.5 BIOLOGICAL ANALYSIS 
The in vitro antimalarial activities were comparing mefloquine and C8-substituted analogs. The 
90% inhibitory concentrations (IC90) against P. falciparum C2A (Pf C2A), a multi-drug resistant 
strain, using mefloquine, chloroquine and pyrimethanmine, were evaluated by Dow et al. at 
WRAIR by using the labeled hypoxanthine assay of Desjardins et al.
62
 as modified by Milhous et 
al.
63
 (Table 8)
64
. None of new analogs were found to be active, suggesting that a strong electron 
withdrawing group on the quinoline is required for antimalarial activity. 
 
 
Table 8. Biological assay results of C8 analogs supplied by WRAIR 
X IC90 [ng/mL] 
-CF3 Mefloquine 68-158 
-Ph rac-23 448 
-Np rac-24 250 
-OH rac-28 485 
-OMe rac-30 274 
-CN rac-33 440 
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3.6 CONCLUSION 
Six new C8-substituted mefloquine analogs were synthesized by recently developed palladium 
cross couplings of chlorides 19 and 20. It was found to be more convenient to prepare the 
mefloquine analogs from 19 because of the easier product purification, but the oxazolidine 
system was not stable enough under harsh conditions. 
The preliminary results of the regioselective coupling reaction for a mefloquine 
derivative precursor are promising for multifunctionalized analogs. Unfortunately, the yields of 
the reaction are low, less than 50%, but an interesting observation was made. The C6 chloride 
site was found to be more active toward the Kumada coupling, whereas, in contrast, the C8 
chloride site was active in the phenol synthesis, even though both reactions are thought to 
proceed by similar palladium-catalyzed mechanisms. The two different transformation of the 
bischloroquinoline developed previously, followed by a platinum-catalyzed reduction, could 
quickly provide a wide variety of bisfunctionalized mefloquine analogs. 
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4.0  EXPERIMENTAL 
4.1 GENERAL 
All moisture-sensitive reactions were performed under an atomosphere of argon gas and 
all glassware was dried in an oven at 140 °C prior to use. THF was distilled over sodium / 
benzophenone ketyl, NMP was distilled over CaH2 and CH2Cl2 was purified using an alumina 
filtration system. Reactions were monitored by TLC analysis (EM Science pre-coated silica gel 
60 F254 plates, 250 m layer thickness) and visualization was accomplished with a 254 nm UV 
light and by staining with a KMnO4 solution (1.5 g of KMnO4 and 2.0 g of K2CO3 in 100 mL of 
a 0.1% NaOH solution) and a ninhydrin solution (0.3 g of ninhydrin and 3 mL of AcOH in 100 
mL of n-BuOH). Chromatography on SiO2 was used to purify the crude reaction mixtures. 
Microwave reactions were performed on a Biotage Initiator microwave reactor. Melting points 
were determined on a Nicolet Avatar 360 FT-IR spectrometer. 
1
H and 
13
C NMR spectra were 
obtained on a Bruker Avance 300 instrument unless otherwise noted. Chemical shifts were 
reported in parts per million with the residual solvent peak used as an internal standard. 
1
H NMR 
spectra were recorded at 300 MHz or 500 MHz and are tabulated as follows: chemical shift, 
multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, br = broad), number 
of protons, and coupling constant(s). 
13
C NMR spectra were recorded at 75 MHz using a proton-
decoupled pulse sequence with a d1 of 3 sec, and are tabulated by observed peak. Mass spectra 
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were obtained on a Micromass Autospec double focusing instrument. Infrared spectra were 
obtained on a Smiths Detection IdentifyIR FT-IR spectrometer (ATR). Optical rotations were 
measured on a Perkin-Elmer 241 polarimeter at 25 °C. Enantiomeric excess were determined by 
HPLC analysisi using AD-H column (0.46 cm X 25 cm): tris (3,5-dimethylphenylcarbamate) 
derivative of amylose coated on silica-gel or by SFC analysis on a Mettler Toledo-MiniGram 
instrument using chiralpac IA column (0.46 cmX 25 cm): tris (3,5-dimethylphenylcarbamate) 
derivative of amylose immobilized on silica-gel. 
 
4.2 EXPERIMENTAL PROCEDURE 
4.2.1 Enantioselective Synthesis of Mefloquine Analogs 
 
8-Chloro-2-(trifluoromethyl)quinoline-4(1H)-one (15). To a vigorously stirred solution of  2-
chloroaniline (3.18 g, 24.4 mmol) in polyphosphoric acid (50 g) was added ethyl 4,4,4-
trifluoroacetoacetate (4.54 g, 24.4 mmol) over 5 min at 100 °C under Ar. The reaction mixture 
was heated to 150 °C for 10 h. After cooling to room temperature, the oily mixture was 
neutralized with a 5% NaOH solution. The precipitate formed was isolated by vacuum filtration, 
washed with water and then re-dissolved in a 10% NaOH solution. The basic yellow solution 
was filtered and then 6 N HCl was added until a pH of 4.5 was achieved. The white precipitate 
 42 
was collected and recrystalized from EtOH/water to afford 15 (4.02 g, 60%) as a white solid: Mp 
134-135 °C; IR (neat) 3245, 3133, 2335,1838, 1515, 1280, 1135 cm
-1
; 
1
H NMR (CDCl3, 300 
MHz) 8.57 (bs, 1 H), 8.28 (d, 1 H, J = 8.4 Hz), 7.78 (dd, 1 H, J = 7.8, 1.2 Hz), 7.39 (t, 1 H, J = 
7.8 Hz), 6.67 (s, 1 H); 
13
C NMR (acetone-d6, 175 MHz) 164.3, 149.6, 145.7, 134.2, 123.3, 
128.0, 123.9, 122.5 (q, JCF = 273.0 Hz), 122.4, 102.1; MS (EI) m/z 247 (M
+
, 100), 219 (23), 199 
(70), 75 (23); HRMS (EI) m/z calcd for C10H5ClF3NO 247.0012, found 247.0023. 
 
 
4-Bromo-8-chloro-2-(trifluoromethyl)quinoline (14). A mixture of 15 (2.21 g, 8.93 
mmol) and POBr3 (2.61 g, 8.93 mmol) was stirred at 150 °C for 30 min under Ar. After cooling 
to room temperature, the reaction mixture was diluted with water and CH2Cl2. The organic layer 
was extracted with CH2Cl2, dried (MgSO4) and concentrated under reduced pressure. The crude 
solid was purified by chromatography on SiO2 (1:9, EtOAc/Hexane) to afford 14 (2.62 g, 95%) 
as a white solid: Mp 68-69 °C; IR (neat) 3096, 3064, 1452, 1323,1258, 1182, 1198, 1129, 1101 
cm
-1
; 
1
H NMR (CDCl3, 300 MHz) 8.22 (dd, 1 H, J = 8.4, 1.2 Hz), 8.10 (s, 1 H), 8.01 (dd, 1 H, 
J = 4.5, 1.2 Hz), 7.70 (t, 1 H, J = 8.1 Hz); 
13
C NMR (CDCl3, 75 MHz) 147.9 (q, JCF = 36.0 Hz), 
144.0, 136.3, 135.2, 131.9, 129.8, 129.7, 125.9, 122.0 (d, JCF = 2.3 Hz), 120.8 (q, JCF = 273.8 
Hz); MS (EI) m/z 313 (25), 311 (M+1, 100), 309 (85), 242 (24); HRMS (EI) m/z calcd for 
C10H4BrClF3N 308.9168, found 308.9157. 
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N-5-Hexyn-1-yl-N,N-di-t-butycarbamate (13). To a solution of 5-hexyn-1-ol (6.00 g, 
59.3 mmol), triphenylphosphine (31.4 g, 119 mmol) and di-t-butyl iminodicarbonate (14.2 g, 
65.2 mmol) in dry THF (400 mL) cooled in an ice bath was added DIAD (24.8 mL, 119 mmol), 
and the reaction mixture was stirred at room temperature for 14 h, and concentrated under 
reduced pressure. The resulting oil was diluted with CH2Cl2, washed with a 10% of 
hydroxyperoxide solution and water, dried (MgSO4) and concentrated under reduced pressure. 
The yellow syrup was purified by chromatography on SiO2 (1:9 Et2O/Hexane) to afford 13 (12.2 
g, 69%) as colorless oil: IR (neat) 3295, 2982, 2937, 1735, 1690, 1366, 1133, 1111 cm
-1
; 
1
H 
NMR (CDCl3, 300 MHz) 5.24 (s, 1 H), 3.50 (t, 2 H, J = 7.2 Hz), 2.13 (td, 1 H, J = 6.9, 2.7 Hz), 
1.87 (d, 1 H, J = 2.7 Hz), 1.68-1.55 (m, 2 H), 1.50-1.47 (m, 1 H), 1.51 (s, 18 H); 
13
C NMR 
(CDCl3, 75 MHz) 152.6, 84.1, 82.1, 68.6, 45.8, 28.2, 28.1, 25.7, 18.2.; HRMS (TOF MS ES+) 
m/z calcd for C16H27NO4Na (M+Na) 320.1838, found 320.1812. 
 
 
N-(E)-6-(8-chloro-2-(trifluoromethyl)quinolin-4-yl)hex-5-en-N,N-di-t-
butylcarbamate (12). A dry flask wrapped with aluminum foil was charged with Cp2ZrHCl (57 
mg, 0.222 mmol) and dry THF (0.5 mL), and 13 (60 mg, 0.202 mmol) was added via a syringe at 
room temperature. After stirring for 1 h, a homogeneous pale yellow solution resulted. A 
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solution of anhydrous ZnCl2 (33 mg, 0.242 mmol) in dry NMP (0.5 mL) was added via a syringe. 
After stirring for 10 min, a mixture of 14 (69 mg, 0.222 mmol) and Pd(PPh3)4 (11 mg, 0.0101 
mmol) dissolved in NMP (0.5 mL) was added, and then the combined mixture was stirred at 
room temperature for 14 h. The reaction was quenched with water and CH2Cl2. The organic layer 
was extracted with CH2Cl2, dried (MgSO4) and concentrated under reduced pressure. The crude 
oil was purified by chromatography on SiO2 (3:7, CH2Cl2/Hexane then 1:4, EtOAc/Hexane) to 
afford 27 mg (25%) of 12 as a colorless oil: IR (neat) 2976, 2932, 1729, 1690, 1454, 1366, 1267, 
1178, 1114 cm
-1
; 
1
H NMR (CDCl3, 300 MHz) 8.10 (d, 1 H, J =8.7 Hz), 7.90 (dd, 1 H, J = 7.2, 
1.2 Hz), 7.79 (s, 1 H), 7.56 (t, 1 H, J = 8.1 Hz), 7.10 (d, 1 H, J = 15.6), 6.59 (dt, 1 H, J = 15.6, 
6.9 Hz), 3.64 (t, 2 H, J = 6.9 Hz), 2.43 (td, 2 H, J = 6.6 Hz), 1.75-1.55 (m, 4 H), 1.51 (s, 9 H); 
13
C NMR (acetone-d6, 75 MHz) 153.0, 148.3 (q, JCF = 34.5 Hz), 146.8, 144.3, 140.5, 135.2, 
130.8, 128.3, 128.1, 124.4, 122.9, 121.7 (q, JCF = 273.8 Hz), 114.0 (d, JCF = 2.3 Hz), 82.4, 46.2, 
33.3, 28.7, 28.3, 26.1; MS (EI) m/z 528 [M
+
] (60), 372 (70), 355 (60), 260 (77), 258 (94), 114 
(100), ; HRMS (EI) m/z calcd for C26H32ClF3N2O4 528.2003, found 528.1987. 
 
 
(-)-(1R,2R)-6-N,N-di-t-butylcarbamic-1-(8-chloro-2-(trifluoromethyl)quinolin-4-
yl)hexane-1,2-diol (11). To a solution of 12 (22 mg, 0.0416 mmol) and methanesulfoneamide 
(6.0 mg, 0.0624 mmol) in a 1:1 mixture of t-BuOH and water (1 mL) was added AD-mix  (77 
mg). After stirring at 0 °C for 24 h, the reaction mixture was quenched with saturated aqueous 
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Na2S2O4 and then extracted with EtOAc. The combined organic layers were washed with brine, 
dried (MgSO4), and concentrated under reduced pressure. The crude yellow oil was purified by 
chromatography on SiO2 (1:4, EtOAc/Hexane) to afford 11 (22 mg, 90%) as white foam. The ee 
(99%) was determined by HPLC using an AD-H column (3%, i-PrOH/Hex): [α]D -28.6 (c 0.35, 
CH3OH); IR (neat) 3409, 2987, 2935, 1768, 1729, 1690, 1367, 1183, 1116 cm
-1
; 
1
H NMR 
(CDCl3, 300 MHz) 7.98 (s, 1 H), 7.91 (d, 1 H, J = 7.2 Hz), 7.89 (d, 1 H, J = 8.4 Hz), 7.58 (dd, 
1 H, J = 8.7, 7.2 Hz), 5.30 (t, 1 H, J = 4.2 Hz), 3.80 (m, 1 H), 3.72 (d, 1 H, J = 4.8 Hz), 3.53 (t, 2 
H, J = 6.3 Hz), 2.71 (d, 1 H, J = 6.0 Hz), 1.70-1.25 (m, 6 H), 1.45 (s, 1 H); 
13
C NMR (CDCl3, 75 
MHz) 153.1, 151.2, 128.2 (q, JCF = 35.3 Hz), 143.9, 135.7, 130.7, 128.6, 128.0, 122.0, 121.6 (q, 
JCF = 273.8 Hz), 116.0, 82.7, 74.8, 72.4, 46.0, 33.5, 28.8, 28.2, 23.0; HRMS (TOF MS ES+) m/z 
calcd for C26H34ClF3N2O5Na (M+Na) 585.1955, found 585.1921. 
 
 
(+)-(1R,2R)-6-N,N-di-t-butylcarbamic-1-(8-chloro-2-(trifluoromethyl)quinolin-4-
yl)hexane-1,2-O-sulfate (10). To an ice-cooled stirred solution of 11 (40.0 mg, 0.0710 mmol) 
and pyridine (23.0 ul, 0.284 mmol) in CH2Cl2 (1 mL) was added thionyl choride (7.9 mL, 0.107 
mmol). The reaction mixture was stirred at room temperature for 20 min, and then diluted with 
CH2Cl2 and water. The organic layer was extracted with CH2Cl2, washed with brine and 
concentrated under reduced pressure. The crude cyclic sulfite was dissolved in a mixture of 
water (0.5 mL), CH3CN (0.25 mL), and CCl4 (0.5 mL). Sodium periodate (23.0 mg, 0.106 mmol) 
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and RuCl3 hydrate (7.1 mg, 0.00710 mmol) were added, and the resulting mixture was 
vigorously stirred at room temperature for 20 h. The reaction mixture was diluted with ethyl 
ether and filtered through a Celite pad. The filtered organic layer was washed with water and 
saturated NaHCO3 solution followed by brine, dried (MgSO4) and concentrated under reduced 
pressure. The crude solid was purified by chromatography on SiO2 (1:4, EtOAc/Hexane) to 
afford 10 (38.0 mg, 85%) as a white solid: [α]D +9.0 (c 0.10, CH3OH); Mp 138-139 °C; IR (neat) 
2982, 2937, 1698, 1392, 1366, 1245, 1210, 1118 cm
-1
; 
1
H NMR (acetone-d6, 300 MHz) 8.44 (d, 
1 H, J = 8.7 Hz), 8.31 (s, 1 H), 8.20 (dd, 1 H, J = 7.5, 0.9 Hz), 7.94 (dd, 1 H, J = 8.7, 7.5 Hz), 
6.94 (d, 1 H, J = 8.1 Hz), 5.48 (ddd, 1 H, J = 10.4, 7.3, 3.0 Hz), 3.49 (t, 2 H, J = 6.8 Hz), 2.81 (m, 
2 H), 2.34-2.24 (m, 1 H), 1.60-1.15 (m, 1 H), 1.43 (s, 18 H), 1.35-1.29 (m, 1 H); 
13
C NMR 
(CDCl3, 75 MHz) 153.0, 148.6 (q, JCF = 36.5 Hz), 144.5, 140.8, 136.7, 131.8, 130.3, 127.2, 
121.1 (q, JCF = 273.8 Hz), 121.0, 116.4 (d, JCF = 1.5 Hz), 88.4, 83.2, 82.6, 45.3, 31.3, 28.2, 28.1, 
22.6; HRMS (TOF MS ES+) m/z calcd for C26H32ClF3N2O8SNa (M+Na) 647.1442, found 
647.1368. 
 
 
(+)-(11R,12S)-8-Chloro2-(trifluoromethyl)quinolin-4-yl-(2-piperidyl)methanol (9). A 
solution of 10 (30.0 mg, 0.0480 mmol) in CH2Cl2 (0.5 mL) was treated with TFA (18.0 uL, 
0.0981 mmol). After stirring at room temperature for 12 h, the solvent was removed under 
reduced pressure. Methanol (0.5 mL) and triethylamine (14.0 uL, 0.0960 mmol) were added to 
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the crude solid and the reaction mixture was heated at reflux for 2 h. After cooling to room 
temperature, the solution was concentrated under reduced pressure. The gray residue was 
dissolved in THF (1 mL), followed by adding a drop of sulfuric acid and water. After stirring for 
1 h at room temperature, the reaction mixture was quenched with saturated NaHCO3 and diluted 
with EtOAc. The organic layer was extracted with EtOAc, washed several times with water and 
brine, dried (MgSO4) and concentrated under reduced pressure. The crude solid was purified by 
chromatography on SiO2 (1:9, MeOH/ CH2Cl2) to afford 9 (10.0 mg, 60%) as a white solid: [α]D 
+30.0 (c 0.10, CH3OH); Mp 203-205 °C; IR (neat) 3096, 2935, 2853, 2717, 1453, 1362, 1261, 
1181, 1129, 1107 cm
-1
; 
1
H NMR (acetone-d6, 300 MHz) 8.35 (d, 1 H, J = 8.7 Hz), 8.14 (s, 1 H), 
8.05 (dd, 1 H, J = 7.5, 1.2 Hz), 7.73 (dd, 1 H, J = 8.4, 7.5 Hz), 5.58 (d, 1 H, J = 4.2 Hz), 3.42 (bs, 
2 H), 3.08-2.95 (m, 2 H), 2.59 (td, 1 H, J = 12.0, 2.7 Hz), 1.75-1.65 (m, 1 H), 1.55-1.40 (m, 1 
Hz), 1.40-1.10 (m, 3 H); 
13
C NMR (acetone-d6, 75 MHz) 154.2, 148.3 (q, JCF = 36.0 Hz), 144.5, 
135.4, 131.6, 129.5, 129.3, 124.5, 122.8 (q, JCF = 272.3 Hz), 116.5, 73.1, 62.1, 47.6, 27.0, 26.8, 
25.0; HRMS (TOF MS ES+) m/z calcd for C16H17ClF3N2O (M+H) 345.0982, found 345.0974. 
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(1R,8aS)-1-(8-Chloro-2-(trifluoromethyl)quinolin-4-yl)-3-isopropylhexahydro-1H-oxazolo[3,4-a] 
pyridine (19). Distilled isobutyraldehyde (1.41 mL, 34.8 mmol) was added into a solution of rac-9 (1.20 g, 
3.48 mmol) in dry CH2Cl2 (35 mL) in the presence of 4 Å molecular sieves. The reaction mixture was 
stirred at room temperature for 20 h. After filtering and washing the flask with more CH2Cl2, the combined 
organic solutions were evaporated under reduced pressure. The crude oil was purified by 
chromatography on SiO2 (1:4, EtOAc/Hexane) to afford 19 (1.24 g, 89%) as a white solid. The ee (99%) 
of 19 prepared from (11R, 12S)-9 was determined by SFC using a Chiral IB column (6% MeOH): Mp 263-
265 °C (decomp.); IR (neat) 2945, 2786, 1456, 1264, 1183, 1131, 1111 cm
-1
; 
1
H NMR (CDCl3, 300 MHz) 
8.29 (s, 1 H), 7.92 (d, 1 H, J = 9.0 Hz), 7.90 (d, 1 H, J = 7.5 Hz), 7.56 (t, 1 H, J = 8.1 Hz), 5.86 (d, 1 H, J 
= 8.7 Hz), 3.85 (s, 1 H), 3.04 (d, 1 H, J = 10.2 Hz), 2.79 (ddd, 1 H, J = 11.1, 8.4, 2.1 Hz), 2.10-1.93 (m, 2 
H), 1.65-1.50 (m, 2 H), 1.40-1.30 (m, 2 H), 1.24 (d, 3 H, J = 6.9 Hz), 1.18 (d, 3 H, J = 6.9 Hz), 1.16-1.12 
(m, 1 H), 0.36 (qd, 1 H, J = 12.0, 3.6 Hz); 
13
C NMR (CDCl3, 75 MHz) 150.6, 148.3 (q, JCF = 35.3 Hz), 
143.7, 135.6, 130.4, 128.5, 128.1, 122.0, 121.8 (q, JCF = 274.5 Hz), 116.8 (d, JCF = 1.5 Hz), 99.5, 74.6, 
67.2, 47.9, 28.9, 26.7, 24.3, 24.1, 19.2, 15.4; HRMS (EI) m/z calcd for C20H22ClF3N2O 398.1373, found 
398.1367. 
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4.2.2 C8-Mefloquine Analogs 
 
General Procedure A. (8-Chloro-2-(trifluoromethyl)quinolin-4-yl)(pyridin-2-yl)methanol 
(20). A solution of 14 (1.80 mg, 5.80 mmol) in dry THF (60 mL) under Ar was reacted with a 2 
M solution of i-PrMgCl in THF (3.19 mL, 6.38 mmol) at 0 °C. After stirring for 1 h, 2-
pyridinecarboxyaldehyde (0.613 mL, 6.38 mmol) was added and the resulting mixture was 
allowed to warm to room temperature over 30 min. The reaction mixture was quenched with 
water and diluted with EtOAc. The organic layer was extracted with EtOAc, washed with brine, 
dried (MgSO4) and concentrated under reduced pressure. The crude solid was purified by 
chromatography on SiO2 (3:7, EtOAc/Hexane) to afford 20 (1.71 g, 87%) as a white solid: Mp 
142-143 °C; IR (neat) 3075, 2831, 2686, 1595, 1454, 1265, 1181, 1111, 1088 cm
-1
; 
1
H NMR 
(CDCl3, 300 MHz) 8.66 (d, 1 H, J =4.8 Hz), 8.14 (dd, 1 H, J = 8.4, 0.9 Hz), 7.94 (s, 1 H), 7.92 
(dd, 1 H, J =7.5, 1.2 Hz), 7.63 (td, 1 H, J = 7.8, 1.8 Hz), 7.56 (dd, 1 H, J = 7.8, 8.4 Hz), 7.29 (dd, 
1 H, J = 7.2, 5.1 Hz), 7.05 (d, 1 H, J = 7.8 Hz), 6.50 (s, 1 H), 5.54 (bs, 1 H); 
13
C NMR (acetone-
d6, 75 MHz) 162.1, 154.5, 149.6, 148.6 (q, JCF = 34.5 Hz), 144.6, 138.2, 135.3, 131.5, 129.4, 
129.1, 125.2 123.8, 122.7 (q, JCF = 273.0 Hz), 122.4, 116.1, 74.0; MS (EI) m/z 338 (M
+
, 50), 321 
(22), 108 (46), 86 (66), 84 (100); HRMS (EI) m/z calcd for C16H10ClF3N2O 338.0434, found 
338.0440. 
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General Procedure B. (±)-8-Chloro-2-(trifluoromethyl)quinolin-4-yl-(2-
piperidyl)methanol (rac-9). To a solution of 20 (200 mg, 0.590 mmol) in EtOH (6 mL) were 
added successively concentrated HCl (49 uL, 0.590 mmol) and PtO2 (7.0 mg) and then the 
reaction mixture was hydrogenated at 5 bar for 3 h at room temperature. After removal of the 
insolubles by filtration through Celite packed with CH2Cl2, the filtrate was washed with saturated 
NaHCO3, water and brine, then dried (MgSO4) and concentrated under reduced pressure. The 
gray solid was purified by chromatography on SiO2 (1:10, MeOH/CH2Cl2) to afford product (184 
mg, 90%) as a gray solid. The diastreomer ratio was 5:1 as determined by 
1
H NMR 
 
 
General Procedure C. (8-Phenyl-2-(trifluoromethyl)quinolin-4-yl)(pyridin-2-
yl)methanol (21). A mixture of 20 (80.0 mg, 0.236 mol), palladium acetate (1.6 mg, 0.00708 
mmol), and tricyclohexylphosphine (4.0 mg, 0.0141 mmol) was dissolved in dry NMP (2 mL) 
under Ar, then Grignard reagent (0.437 mL of 1.35 M solution) generated from bromobenzene 
was added by syringe. The reaction mixture was stirred at 50 °C for 6 h. After cooling to room 
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temperature, the reaction was quenched with saturated NH4Cl and diluted with EtOAc. The 
organic layer was extracted with EtOAc, washed with water several times, dried (MgSO4) and 
concentrated under reduced pressure. The crude oil was purified by chromatography on SiO2 (1:4, 
EtOAc/Hexane) to afford 21 (70.0 mg, 78%) of as a pink solid: Mp 117-118 °C; IR (neat) 3347, 
2961, 1632, 1550, 1444, 1358, 1288, 1202 cm
-1
; 
1
H NMR (CDCl3, 300 MHz) 8.67 (d, 1 H, J = 
4.8 Hz), 8.20 (d, 1 H, J = 6.6 Hz), 7.89 (s, 1 H), 7.86 (dd, 1 H, J = 7.2, 1.5 Hz), 7.77-7.68 (m, 2 
H), 7.63 (td, 1 H, J = 7.8, 1.5 Hz), 7.53-7.40 (m, 3 H), 7.29 (dd, 1 H, J = 7.2, 5.4 Hz), 7.11 (d, 1 
H, J = 7.8 Hz), 6.56 (s, 1 H), 5.59 (bs, 1 H); 
13
C NMR (CDCl3, 75 MHz) 159.2, 150.5, 148.6, 
147.4 (q, JCF = 35.3 Hz), 145.5, 142.3, 138.8 137.7 131.3, 131.2, 128.7, 127.4, 123.6, 123.5, 
121.8 (q, JCF = 273.8 Hz), 121.6, 115.4 (d, JCF = 1.5 Hz), 72.4; HRMS (TOF MS ES+) m/z calcd 
for C22H15F3N2ONa (M+Na) 403.1034, found 403.0999. 
 
 
(±)-(8-Phenyl-2-(trifluoromethyl)quinolin-4-yl)(piperidin-2-yl)methanol (rac-23). 
According to general procedure B, to a solution of 21 (70.0 mg, 0.184 mmol) in EtOH (2 mL) 
were added successively 6 N HCl (15.0 uL, 0.184 mmol) and PtO2 (2.0 mg, 0.00920 mmol) and 
then hydrogenated at ballon pressure for 6 h at room temperature. After removal of the insolubles 
by filtration through Celite, the filtrate was diluted with water and ether. The organic layer was 
washed with sat. NaHCO3 solution and brine, then dried (MgSO4) and concentrated in vacuo. 
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The residue was purified by chromatography on SiO2 (10% MeOH/DCM), then purified by 
Preparative TLC (10% MeOH/DCM) to afford rac-23 (35.0 mg, 49%) of product as a white 
solid; Mp 230-232 °C; IR (neat) 3207, 2926, 2853, 1442, 1264, 1180, 1131, 1109 cm
-1
;
 1
H NMR 
(acetone-d6, 500 MHz) 8.44 (d, 1 H, J = 8.5 Hz), 8.11 (s, 1 H), 7.81 (d, 1 H, J = 7.0 Hz), 7.80-
7.63 (m, 2 H), 7.47-7.40 (m, 3 H), 6.07 (s, 1 H), 4.98 (bs, 2 H), 3.41-3.32 (m, 2 H), 3.00-2.85 (m, 
1 H), 1.74-1.63 (m, 3 H), 1.32-1.29 (m, 3 H), 0.87-0.83 (m, 1 H); 
13
C NMR (acetone-d6, 75 
MHz) 153.0, 147.3 (d, JCF = 33.8 Hz), 145.7, 142.8, 140.0, 132.1, 131.9, 129.4, 128.7, 128.4, 
128.1, 124.4, 123.0 (d, JCF = 273.0 Hz), 115.4, 72.7, 61.7, 47.4, 26.7, 26.3, 24.9. 
 
 
(8-Neopentyl-2-(trifluoromethyl)quinolin-4-yl)(pyridin-2-yl)methanol (22). 
According to general procedure C, a mixture of 20 (100 mg, 0.295 mol), palladium acetate (4.2 
mg, 0.00886 mmol), and tricyclohexylphosphine (5.0 mg, 0.0177 mmol) was dissolved in dry 
NMP (2 mL) under Ar, then Grignard reagent prepared from 1-bromo-2,2-dimethylpropane (0.53 
mL of 1.4 M solution) was added. The reaction mixture was stirred at 50 °C for 6 h. The crude 
oil was purified by chromatography on SiO2 (1:4, EtOAc/Hexane) to afford 22 (78.0 mg, 71%) 
as a white solid: Mp 124-126 °C; IR (neat) 3340, 2950, 2863, 1681, 1593, 1470, 1362, 1178, 
1133 cm
-1
; 
1
H NMR (acetone-d6, 300 MHz) 8.48 (d, 1 H, J = 7.8 Hz), 8.33 (dd, 1 H, J = 8.1, 
1.8 Hz), 8.15 (s, 1 H), 7.77 (td, 1 H, J = 7.8, 1.8 Hz), 7.70-7.60 (m, 2 H), 7.25 (ddd, 1 H, J = 7.5, 
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4.8, 1.2 Hz), 6.68 (d, 1 H, J = 3.9 Hz), 5.80 (d, 1 H, J = 4.5 Hz), 3.34, 3.23 (AB, 2 H, J = 12.3 
Hz), 0.91 (s, 9 H); 
13
C NMR (CDCl3, 75 MHz) 159.5, 150.2, 148.5, 147.3, 146.5 (q, JCF = 34.5 
Hz), 141.2, 137.7, 132.3, 128.1, 127.5, 127.0, 123.4, 122.2, 122.0 (q, JCF = 273.8 Hz), 121.6, 
114.8, 72.3, 43.7, 33.2, 30.0; HRMS (TOF MS ES+) m/z calcd for C21H21F3N2O 375.1684, found 
375.1653. 
 
 
(±)-(8-Neopentyl-2-(trifluoromethyl)quinolin-4-yl)(piperidin-2-yl)methanol (rac-24). 
According to general procedure B, to a solution of 22 (50.0 mg, 0.134 mmol) in EtOH (1.5 mL) 
were added 6 N HCl (11 uL, 0.134. mmol) and PtO2 (1.5 mg, 0.00668 mmol) and then the 
reaction mixture was hydrogenated at ballon pressure at room temperature for 5 h. The gray solid 
was purified by chromatography on SiO2 (1:9, MeOH/CH2Cl2) to afford rac-24 (40.0 mg, 79%) 
as a gray solid; Mp 215-117 °C; IR (neat) 3100, 2937, 2868, 2667, 1461, 1360, 1274, 1183, 1135, 
1103 cm
-1
; 
1
H NMR (CD2Cl2, 300 MHz) 7.97 (s, 1 H), 7.89 (dd, 1 H, J = 8.1, 1.8 Hz), 7.76-
7.57 (m, 2 H), 5.45 (d, 1 H, J = 3.3 Hz), 3.35, 3.24 (AB, 2 H, J = 12.3 Hz), 3.17-3.05 (m, 2 H), 
2.73 (td, 1 H, J = 12.0, 2.7 Hz), 1.70-1.60 (m, 2 H), 1.60-1.50 (m, 2 H), 1.40-1.23 (m, 3 H), 1.18-
1.05 (m, 1 H), 0.93 (s, 9 H); 
13
C NMR (DMSO-d6, 150 MHz) 153.1, 145.9, 144.5 (q, JCF = 34.5 
Hz), 139.4, 132.2, 127.9 (q, JCF = 273.0 Hz), 126.7, 122.4, 121.9, 113.8, 71.6, 61.2, 46.5, 42.8, 
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32.7, 29.7, 26.3, 26.1, 24.0; HRMS (TOF MS ES+) m/z calcd for C21H27F3N2ONa (M+Na) 
403.1973, found 403.1994. 
 
 
(±)-3-Isopropyl-1-(8-phenyl-2-(trifluoromethyl)quinolin-4-yl)hexahydro-1H-oxazolo 
pyridine (rac-25). According to general procedure C, a mixture of rac-19 (50.0 mg, 0.125 mol), 
palladium acetate (0.8 mg, 0.00376 mmol), and tricyclohexylphosphine (2.1 mg, 0.00752 mmol) 
was dissolved in dry NMP (1.2 mL) under Ar, then Grignard reagent prepared from 
bromobenzene (0.125 mL of 2 M solution, 0.251 mmol) was added. The reaction mixture was 
stirred at 50 °C for 6 h. The crude oil was purified by chromatography on SiO2 (1:20,  
EtOAc/Hexane) to afford rac-25 (28.0 mg, 51%) as yellow oil: IR (neat) 2928, 2850, 1461, 1260, 
1178, 1131, 1107 cm
-1
; 
1
H NMR (CDCl3, 300 MHz) 8.22 (s, 1 H), 8.09 (dd, 1 H, J = 8.4, 1.2 
Hz), 7.85 (dd, 1 H, J = 4.5, 1.5 Hz), 7.80-7.77 (m, 2 H), 7.70 (dd, 1 H, J = 8.4, 4.2 Hz), 7.53-7.42 
(m, 3 H), 5.94 (d, 1 H, J = 8.4 Hz), 3.87 (d, 1 H, J = 2.1 Hz), 3.06 (d, 1 H, J = 10.5 Hz), 2.83 
(ddd, 1 H, J = 11.1, 8.7, 2.4 Hz), 2.15-1.95 (m, 2 H), 1.65-1.55 (m, 2 H), 1.49-1.35 (m, 2 H), 
1.25 (d, 3 H, J = 6.9 Hz), 1.19 (d, 1 H, J = 7.5 Hz), 1.00-0.85 (m, 1 H), 0.47 (, 1 H, J =  Hz); 
13
C 
NMR (CDCl3, 75 MHz) 149.6, 147.3 (d, JCF = 36.0 Hz), 144.8, 142.3, 139.0, 131.3, 130.9, 
128.0, 128.0, 127.7, 127.6, 122.4, 122.0, 115.8, 99.5, 67.3, 48.1, 29.0, 26.8, 24.4, 24.2, 19.2, 
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15.5.; MS (EI) 440 (M
+
, 42), 397 (100), 381 (98), 355 (63), 325 (42), 321 (95), 293 (40), 140 
(70), 125 (60); m/z HRMS (EI) m/z calcd for C26H27F3N2O 440.2075, found 440.2068. 
 
 
General procedure D. 4-(Hydroxy(pyridin-2-yl)methyl)-2-(trifluoromethyl)quinolin-
8-ol (27). A mixture of 20 (100 mg, 0.295 mmol), tris(dibenzylideneacetone)dipalladium (5.5 mg, 
0.00590 mmol), 2-di-t-butylphosphino-2',4',6'-tri-i-propyl-1',1'-biphenyl (6.5 mg, 0.00646 mmol) 
and KOH (22.6 mg, 0.354 mmol) was added to a microwave tube and then flushed with Ar. A 
1:1 mixture of degassed water and dioxane (3 mL) was added and the resulting mixture was 
irradiated at 120 °C for 30 min in the microwave. After cooling to room temperature, the reaction 
mixture was acidified with dilute aqueous HCl. The resulting solution was extracted with EtOAc, 
dried (MgSO4) and concentrated under reduced pressure. The crude solid was purified by 
chromatography on SiO2 (1:4, EtOAc/Hexane) to afford 27 (56 mg, 56%) as a white solid: Mp 
123-124 °C; IR (neat) 3384, 3295, 3032, 2617, 1508, 1472, 1366, 1191, 1129, 1105 cm
-1
; 
1
H 
NMR (CDCl3, 300 MHz) 8.66 (d, 1 H, J = 4.8 Hz), 8.14 (s, 1 H), 7.93 (s, 1 H), 7.70 (d, 1 H, J 
= 4.2 Hz), 7.65-7.55 (m, 2 H), 7.35-7.23 (m, 1 H), 7.10 (d, 1 H, J = 7.8 Hz), 6.51 (d, 1 H, J = 3.6 
Hz), 5.55 (s, 1 H); 
13
C NMR (acetone-d6, 75 MHz) 162.3, 154.8, 154.0, 149.6, 146.0 (q, JCF = 
34.5 Hz), 138.8, 138.1, 130.9, 128.3, 123.8, 123.8, 122.9 (q, JCF = 273.0 Hz), 122.4, 116.0, 115.6 
(d, JCF = 2.3 Hz), 112.6, 74.0; MS (EI) 320 (M
+
, 42), 303 (15), 108 (90), 84 (100); m/z HRMS 
(EI) m/z calcd for C16H11F3N2O2 320.0773, found 320.0783. 
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(±)-4-(Hydroxy(piperidin-2-yl)methyl)-2-(trifluoromethyl)quinolin-8-ol (rac-29). 
According to general procedure B, to a solution of 27 (70.0 mg, 0.219 mmol) in EtOH (2 mL) 
were added 6 N HCl (18.2 uL, 0.219 mmol) and PtO2 (2.5 mg, 0.0109 mmol) and then the 
reaction mixture was hydrogenated at ballon pressure at room temperature for 6 h. The crude 
solid was purified by chromatography on SiO2 (1:9, MeOH/CH2Cl2) to afford rac-28 (30.0 mg, 
38%) as a yellow solid: Mp 232-235 °C; IR (neat) 3265, 3082, 2948, 2868, 1351, 1260, 1170, 
1118 cm
-1
; 
1
H NMR (DMSO-d6, 300 MHz) 7.91 (s, 1 H), 7.69 (d, 1 H, J = 8.1 Hz), 7.60 (dd, 1 
H, J = 8.4, 7.5 Hz), 7.23 (d, 1 H, J = 7.2 Hz), 5.76 (bs, 1 H), 5.27 (d, 1 H, J = 4.2 Hz), 3.34 (bs, 2 
H), 2.92 (d, 1 H, J = 12.0 Hz), 2.85-2.75 (m, 1 H), 2.43, 1.73-1.60 (m, 1 H), 1.48-1.37 (m, 4 H), 
1.37-1.10 (m, 1 H); 
13
C NMR (DMSO-d6, 75 MHz) 154.3, 152.7, 143.8 (d, JCF = 33.8 Hz), 
137.9, 129.6, 127.7, 121.8 (d, JCF = 273.0 Hz), 114.5, 113.9, 112.5, 71.7, 61.1, 46.5, 26.2, 26.1, 
24.1; HRMS (TOF MS ES+) m/z calcd for C16H17F3N2O2 (M+H) 327.1320, found 327.1310.  
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(±)-4-(3-Isopropylhexahydro-1H-oxazolopyridin-1-yl)-2-(trifluoromethyl)quinolin-8-
ol (rac-31). Distilled isobutyraldehyde (12.0 uL, 0.306 mmol) was added into a solution of 30 
(20.0 mg, 0.0613 mmol) in dry CH2Cl2 (1 mL) in the presence of 4 Å molecular sieves, then the 
solution was stirred at room temperature for 20 h. After passing through short silica column and 
concentrating under reduced puressure, rac-31 (23.0 mg, 94%) was isolated as pale yellow oil. 
The crude rac-31 was pure enough and used next step without further purification: IR (neat) 
3422, 2937, 2794, 1513, 1472, 1133 cm
-1
;
 1
H NMR (CDCl3, 500 MHz) 8.25 (s, 1 H), 8.15 (bs, 
1 H), 7.56 (t, 1 H, J = 8.0 Hz), 7.45 (d, 1 H, J = 8.5 Hz), 7.25 (d, 1 H, J = 7.5 Hz), 5.84 (d, 1 H, J 
= 8.5 Hz), 3.85 (d, 1 H, J = 1.5 Hz), 3.04 (d, 1 H, J = 10.0 Hz), 2.79 (ddd, 1 H, J = 6.6, 5.4, 1.2 
Hz), 2.11-2.03 (m, 1 H), 1.99 (ddd, 1 H, J = 7.5, 6.0, 1.5 Hz), 1.63-1.55 (m, 2 H), 1.43-1.35 (m, 
2 H), 1.24 (d, 3 H, J = 7.0 Hz), 1.18 (d, 3 H, J = 7.0 Hz), 1.15-1.10 (m, 1 H), 0.39 (qd, 1 H, J = 
6.9, 2.1 Hz); 
13
C NMR (CDCl3, 125 MHz) 153.3, 150.6, 145.5 (d, JCF = 35.0 Hz), 137.3, 129.8, 
127.6, 121.8 (d, JCF = 273.8 Hz), 116.5, 113.5, 110.8, 99.6, 74.7, 67.3, 48.0, 29.0, 26.6, 24.4, 
24.1, 19.2, 15.4; MS (EI) m/z 379 (10), 338 (75), 337 (M-i-Pr, 100), 309 (72), 139 (90), 124 (89); 
HRMS (EI) m/z calcd for C17H16F3N2O2 [M-(i-Pr)] 337.1164, found 337.1166. 
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(±)-(8-Methoxy-2-(trifluoromethyl)quinolin-4-yl)(piperidin-2-yl)methanol (rac-30). 
To a solution of 31 (15 mg, 0.0394 mmol) and K2CO3 (5.4 mg, 0.0394 mmol) dissolved in 
CH2Cl2 (0.5 mL) was added MeI (7.4 uL, 0.118 mmol) by a syringe. After stirring at room 
temperature for 8 h, the reaction mixture was diluted with water and extracted with CH2Cl2. The 
organic layer was washed with saturated NH4Cl and brine, dried (MgSO4) and concentrated 
under reduced pressure. The crude oil was dissolved in MeOH (0.3 mL), followed by the 
addition of 2,2-dimethyl-1,3-propanediol (21.2 mg, 0.197 mmol) and pTsOH (7.5 mg, 0.0394 
mmol). The reaction mixture was stirred at room temperature for 14 h. After diluting with ether 
and water, the organic layer was extracted, washed with saturated NaHCO3 solution and brine, 
then dried (MgSO4) and concentrated under reduced pressure. The residue was purified by 
chromatography on SiO2 (first EtOAc to remove 2,2-dimethyl-1,3-propanediol then 1:4, 
MeOH/CH2Cl2) to afford rac-30 (8 mg, 60%) as a white solid: IR (neat) 3327, 2932, 2855, 1604, 
1437, 1178, 1131, 1109 cm
-1
; 
1
H NMR (acetone-d6, 300 MHz) 8.07 (s, 1 H), 7.83 (d, 1 H, J = 
8.7 Hz), 7.62 (dd, 1 H, J = 8.4, 8.1 Hz), 7.27 (d, 1 H, J = 7.8 Hz), 5.69 (d, 1 H, J = 3.3 Hz), 4.30 
(bs, 2 H), 4.04 (s, 3 H), 3.28 (d, 2 H, J = 11.1 Hz), 2.76 (td, 1 H, J = 11.7, 2.7 Hz), 1.78-1.67 (m, 
1 H), 1.65-1.40 (m, 1 H), 1.35-1.15 (m, 1 H), 0.92-0.83 (m, 1 H); 
13
C NMR (acetone-d6, 75 
MHz) 157.5, 52.1, 146.3 (d, JCF = 33.8 Hz), 140.4, 130.0, 128.8, 123.1 (d, JCF = 272.3 Hz), 
116.0, 115.7, 109.8, 72.5, 61.5, 56.4, 26.6, 24.8, 23.4. 
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(±)-4-(3-Isopropylhexahydro-1H-oxazolopyridin-1-yl)-2-(trifluoromethyl)quinoline-
8-carbonitrile (rac-32). A mixture of rac-19 (100 mg, 0.251 mmol), zinc cyanide (17.8 mg, 
0.150 mmol), Pd2dba3 (7.0 mg, 0.00752 mmol) and S-Phos (6.2 mg, 0.0150 mmol) was dissolved 
in dry NMP (2.5 mL) under Ar. The reaction mixture was irradiated at 130 °C for 30 min in the 
microwave. The resulting solution was quenched with saturated NH4Cl and diluted with EtOAc. 
The organic layer was extracted with EtOAc, washed with water and brine, dried (MgSO4) and 
concentrated under reduced pressure. The crude residue was purified by chromatography on SiO2 
(1:4, EtOAc/Hexane) to afford rac-32 (46 mg, 47%) as a white solid: Mp 127-128 °C; IR (neat) 
2950, 2812, 2235, 1470, 1269, 1174, 1131 cm
-1
; 
1
H NMR (CDCl3, 300 MHz) 8.34 (s, 1 H), 
8.28 (dd, 1 H, J = 8.7, 0.6 Hz), 8.21 (dd, 1 H, J = 7.2, 0.9 Hz), 7.73 (dd, 1 H, J = 7.2, 7.2 Hz), 
5.86 (d, 1 H, J = 8.4 Hz), 3.86 (d, 1 H, J = 2.4 Hz), 3.05 (d, 1 H, J = 10.5 Hz), 2.82 (ddd, 1 H, J = 
11.1, 8.7, 2.1 Hz), 2.15-1.95 (m, 2 H), 1.65-1.55 (m, 2 H), 1.40-1.25 (m, 2 H), 1.23 (d, 3 H, J = 
6.9 Hz), 1.17(d, 1 H, J = 7.2 Hz), 0.97 (d, 1 H, J = 6.6 Hz), 0.35 (qd, 1 H, J = 11.7, 3.6 Hz); 
13
C 
NMR (CDCl3, 75 MHz) 151.0, 149.8 (q, JCF = 35.3 Hz), 146.3, 136.4, 128.0, 127.5, 127.2, 
121.4, 117.8, 116.6, 115.1, 99.7, 74.4, 67.1, 47.9, 28.9, 26.8, 24.3, 24.1, 19.1, 15.4; MS (EI) m/z 
389 [M
+
] (21), 347 (85), 346 (100), 318 (86), 319 (57), 318 (91), 139 (77), 124 (75); HRMS (EI) 
m/z calcd for C21H22F3N3O 389.1715, found 389.1706. 
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(±)-4-(Hydroxy(piperidin-2-yl)methyl)-2-(trifluoromethyl)quinoline-8-carbonitrile 
(rac-33). According to general procedure B, a mixture of rac-32 (30.0 mg, 0.0770 mmol), 2,2-
dimethyl-1,3-propanediol (40.0 mg, 0.385 mmol) and p-TsOH (23.0 mg, 0.116 mmol) in MeOH 
(1 mL) was stirred at room temperature for 14 h. After diluting with Ether and water, the organic 
layer was extracted, washed with saturated NaHCO3 solution and brine, then dried (MgSO4) and 
concentrated under reduced pressure. The crude solid was purified by chromatography on SiO2 
(first EtOAc then 1:4, MeOH/CH2Cl2) to afford rac-33 (22.0 mg, 85%) as a white solid; Mp 239-
241 °C; IR (neat) 3258, 2924, 2851, 2725, 2334, 1600, 1366, 1267, 1185, 1137, 1114 cm
-1
; 
1
H 
NMR (acetone-d6, 300 MHz) 8.85 (d, 1 H, J = 8.7 Hz), 8.29 (dd, 1 H, J = 7.2, 1.2 Hz), 8.21 (s, 
1 H), 7.65 (dd, 1 H, J = 8.4, 7.5 Hz), 6.15 (d, 1 H, J = 2,7 Hz), 3.98 (bs, 2 H), 3.45-3.35 (m, 2 H), 
2.97 (td, 1 H, J = 11.7, 3.9 Hz), 1.80-1.60 (m, 2 H), 1.40-1.20 (m, 4 H); 
13
C NMR (acetone-d6, 
75 MHz) 153.1, 149.5 (d, JCF = 34.5 Hz), 138.0, 130.3, 129.0, 127.3, 122.5 (d, JCF = 273.0 Hz), 
117.2, 116.9, 114.9, 70.1, 61.1, 46.3, 32.4, 24.3, 23.2, 14.4;  HRMS (EI) m/z calcd for 
C17H15F3N3 (M-OH) 318.1218, found 318.1206. 
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(±)-4-(3-Isopropylhexahydro-1H-oxazolopyridin-1-yl)-2-(trifluoromethyl)quinoline-
8-carboxamide (rac-35). To a solution of rac-32 (55.0 mg, 0.141 mmol) in DMSO (1.5 mL) 
were added K2CO3 (58.6 mg, 0.424 mmol) and 30% H2O2 (48 uL, 0.424 mmol) and then the 
reaction mixture was kept stirring at 60 °C for 6 h. After cooling to room temperature, the 
reaction mixture was diluted with water and EtOAc. The organic layer was extracted, washed 
several times with water and brine, dried (MgSO4) and then concentrated under reduced pressure. 
The crude oil was purified by chromatography on SiO2 (3:7, EtOAc/Hex) to afford rac-35 (52 
mg, 90%) as a pink solid: Mp 220-222 °C; IR (neat) 3345, 3164, 2940, 2794, 1677, 1569, 1424, 
1180, 1137  cm
-1
; 
1
H NMR (CDCl3, 300 MHz) 10.48 (bs, 1 H), 8.95 (dd, 1 H, J = 7.2, 1.2 Hz), 
8.31 (s, 1 H), 8.20 (d, 1 H, J = 7.8 Hz), 7.80 (t, 1 H, J = 7.8 Hz), 6.26 (bs, 1 H), 5.92 (d, 1 H, J = 
8.7 Hz), 3.87 (d, 1 H, J = 2.1 Hz), 3.05 (d, 1 H, J = 9.9Hz), 2.83 (ddd, 1 H, J = 11.1, 8.7, 2.1 Hz), 
2.15-1.95 (m, 2 H), 1.65-1.55 (m, 2 H), 1.45-1.30 (m, 2 H), 1.25 (d, 3 H, J = 6.9 Hz), 1.18 (d, 3 
H, J = 7.2 Hz), 1.15-1.10 (m, 1 H), 0.36 (qd, 1 H, J = 12.0, 3.3 Hz); 
13
C NMR (CDCl3, 75 MHz) 
167.0, 152.0, 146.9 (q, JCF = 36.0 Hz), 144.3, 135.3, 130.2, 128.1, 127.4, 127.2, 121.7 (d, JCF = 
272.3 Hz), 115.9, 99.6, 74.7, 67.2, 48.0, 28.9, 26.9, 24.3, 24.1, 19.2, 15.5; HRMS (TOF MS 
ES+) m/z calcd for C21H25F3N3O2 (M+H) 408.1899, found 408.1864. 
 
 62 
 
(±)-4-(Hydroxy(piperidin-2-yl)methyl)-2-(trifluoromethyl)quinoline-8-carboxamide 
(rac-36). According to general procedure F, a reaction mixture of rac-35 (20.0 mg, 0.0491 
mmol), 2,2-dimethyl-1,3-propanediol (25.8 mg, 0.245 mmol) and p-TsOH (8.4 mg, 0.0736 
mmol) in MeOH (0.5 mL) was stirred at room temperature for 14 h. After diluting with Ether 
and water, the organic layer was extracted, washed with saturated NaHCO3 solution and brine, 
then dried (MgSO4) and concentrated under reduced pressure. The residue was purified by 
chromatography (first EtOAc then 1:9, MeOH/CH2Cl2) to afford rac-36 (16.0 mg, 92%) as a 
white solid: IR (neat) 3258, 2924, 2850, 1668, 1565, 1428, 1263, 1181, 1127 cm
-1
; 
1
H NMR 
(DMSO-d6, 300 MHz) 9.29 (bs, 1 H), 8.56 (d, 1 H, J = 8.7 Hz), 8.54 (d, 1 H, J = 6.0 Hz), 8.04 
(s, 1 H), 8.00 (bs, 1 H), 7.90 (t, 1 H, J = 7.8 Hz), 5.96 (bs, 1 H), 5.37 (d, 1 H, J = 4.2 Hz), 3.31 
(bs, 2 H), 2.95-2.75 (m, 2 H), 2.41 (t, 1 H, J = 10.7 Hz), 1.72-1.65 (m, 1 H), 1.50-1.35 (m, 1 H), 
1.30-1.10 (m, 3 H); 
13
C NMR (DMSO-d6, 75 MHz) 166.4, 155.0, 145.2 (d, JCF = 33.8 Hz), 
143.6, 133.1, 132.1, 128.2, 127.8, 127.0, 121.8 (d, JCF = 273.0 Hz), 114.7, 71.8, 61.6, 46.4, 26.6, 
25.9, 24.0; HRMS (EI) m/z calcd for C17H18F3N3O2 353.1351, found 353.1353. 
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6-Chloro-4-(hydroxy(pyridin-2-yl)methyl)-2-(trifluoromethyl)quinolin-8-ol (45). 
According to general procedure A, 2-bromo-6,8-bischloro-2-(trifluoromethyl)quinolin (2.00 g, 
5.80 mmol) was dissolved in dry THF (60 mL) under Ar, and then a 2 M solution of i-PrMgCl in 
THF (3.18 mL, 6.38 mmol) was added at 0 °C. After stirring for 1 h, 2-pyridinecarboxyaldehyde 
(0.613 mL, 6.38 mmol) was added and the resulting mixture was allowed to warm to room 
temperature over 30 min. The crude residue was purified by chromatography on SiO2 (3:7, 
EtOAc/Hexane) to afford 45 (1.42 g, 65%) as a yellow solid: Mp 135-136 °C; IR (neat) 3400, 
3088, 1593, 1448, 1185, 1139, 1090 cm
-1
; 
1
H NMR (CDCl3, 300 MHz) 8.69 (dd, 1H, J = 4.8, 
0.9 Hz), 8.18 (d, 1H, J = 2.1 Hz), 7.90 (d, 1H, J = 2.4 Hz), 7.89 (s, 1H), 7.06 (d, 1H, J = 8.1 Hz), 
7.32 (dd, 1H, J = 7.2, 4.8 Hz), 7.06 (d, 1H, J = 8.1 Hz), 6.40 (s, 1H), 5.42 (d, 1H, J = 2.7 Hz); 
13
C NMR (acetone-d6, 75 MHz) 162.0, 154.2, 149.7, 148.9 (q, JCF = 34.5 Hz), 143.3, 138.3, 
136.6, 134.3, 131.8, 129.4, 124.6, 123.9, 122.6 (q, JCF = 262.5 Hz), 122.3, 117.2 (d, JCF = 2.3 Hz), 
73.9; MS (EI) 374 (45), 373 (35), 372 (M
+
, 72), 371 (45), 353 (20), 355 (22), 108 (94), 79 (100); 
m/z HRMS (EI) m/z calcd for C16H10ClF3N2O2 372.0044, found 372.0033. 
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(8-Chloro-6-phenyl-2-(trifluoromethyl)quinolin-4-yl)(pyridin-2-yl)methanol (46). 
According to general procedure B, a mixture of 45 (80.0 mg, 0.214 mol), palladium acetate (1.4 
mg, 0.00642 mmol), tricyclohexylphosphine (3.6 mg, 0.0128 mmol) was dissolved in dry NMP 
(1.5 mL) under Ar. After cooling to 0 °C, Grignard reagent prepared from bromobenzene (0.429 
mL of 1.25 M solution in THF) was added by syringe. The reaction mixture was kept stirring at 
0 °C for 12 h. The crude solid was purified by chromatography on SiO2 (1:4, EtOAc/Hexane) to 
afford 46 (37.0 mg, 42%) as a white solid: IR (neat) 3450, 3071, 2926, 2855, 1593, 1457, 1277, 
1183, 1134 cm
-1
; 
1
H NMR (CDCl3, 500 MHz) 8.69 (d, 1 H, J = 5.0 Hz), 8.33 (d, 1 H, J = 2.0 
Hz), 8.20 (d, 1 H, J = 1.5 Hz), 7.94 (s, 1 H), 7.65 (td, 1 H, J = 7.5, 1.5 Hz), 7.62 (d, 2 H, J = 7.0 
Hz), 7.51 (t, 2 H, J = 7.5 Hz), 7.46 (d, 1 H, J = 7.5 Hz), 7.31 (dd, 1 H, J = 7.0, 5.0 Hz), 7.10 (d, 1 
H, J = 8.0 Hz), 6.54 (s, 1 H), 5.49 (s, 1 H); 
13
C NMR (CDCl3, 75 MHz) 158.7, 151.2, 148.9, 
148.2 (q, JCF = 35.3 Hz), 143.7, 141.6, 138.9, 137.8, 135.9, 130.4, 129.4, 128.9, 128.5, 127.7, 
123.7, 121.6 (q, JCF = 273.8 Hz), 121.5, 120.9, 116.9, 72.5HRMS (EI) m/z calcd for 
C22H15ClF3N2O (M+H) 415.0825, found 415.0819. 
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6-Chloro-4-(hydroxy(pyridin-2-yl)methyl)-2-(trifluoromethyl)quinolin-8-ol (49). A 
mixture of 45 (80.0 mg, 0.214 mmol), tris(dibenzylideneacetone)dipalladium (5.9 mg, 0.00643 
mmol), 2-di-t-butylphosphino-2',4',6'-tri-i-propyl-1',1'-biphenyl (6.0 mg, 0.0129 mmol) and 
KOH (19.1 mg, 0.300 mmol) was added to a microwave tube. A 1:1 mixture of degassed water 
and dioxane (2 mL) was added and the resulting mixture was irradiated at 120 °C for 30 min in 
the microwave. The crude solid was purified by chromatography on SiO2 (1:4, EtOAc/Hexane) 
to afford 49 (32.0 mg, 42%) as a white solid: Mp 131-133 °C; IR (neat) 3403, 3075, 1595, 1505, 
1275, 1183, 1137 cm
-1
; 
1
H NMR (CDCl3, 300 MHz) 8.67 (d, 1 H, J = 4.8 Hz), 8.19 (s, 1 H), 
7.92 (s, 1 H), 7.70 (d, 1 H, J = 2.1 Hz), 7.66 (td, 1 H, J = 7.8, 1.8 Hz), 7.31 (dd, 1 H, J = 6.9, 4.8 
Hz), 7.26 (d, 1 H, J = 2.1 Hz), 7.10 (d, 1 H, J = 8.1 Hz), 6.40 (s, 1 H), 5.53 (d, 1 H, J = 3.0 Hz); 
13
C NMR (CDCl3, 75 MHz) 158.1, 154.0 150.8, 148.8, 145.9 (d, JCF = 35.3 Hz), 137.8, 136.8, 
136.7, 128.0, 123.8, 121.4 (d, JCF = 273.0 Hz), 117.3, 114.0, 112.9, 71.7; MS (EI) 356 (46), 355 
(40), 354 (M
+
, 89), 353 (45), 319 (40), 108 (89), 79 (100); HRMS (EI) m/z calcd for 
C16H10ClF3N2O2 354.0383, found 354.0379. 
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(6-Chloro-8-methoxy-2-(trifluoromethyl)quinolin-4-yl)(pyridin-2-yl)methanol (50). 
To a solution of 45 (20.0 mg, 0.0564 mmol) and K2CO3 (11.7 mg, 0.0846 mmol) in CH2Cl2 (0.5 
mL) was added MeI (10.5 uL, 0.169 mmol) by a syringe. After stirring at room temperature for 8 
h, the reaction mixture was diluted with water and extracted with CH2Cl2. The organic layer was 
washed with saturated NH4Cl and brine, dried (MgSO4) and concentrated under reduced pressure. 
The crude solid was purified by chromatography on SiO2 (1:4, EtOAc/Hexane) to afford 50 (18.0 
mg, 87%) as a white solid: Mp 155-156 °C; IR (neat) 3400, 2922, 2851, 1595, 1540, 1256, 1180, 
1133 cm
-1
; 
1
H NMR (CDCl3, 500 MHz) 8.66 (d, 1 H, J = 4.5 Hz), 7.89 (s, 1 H), 7.77 (d, 1 H, J 
= 2.0 Hz), 7.65 (td, 1 H, J = 7.5, 1.5 Hz), 7.30 (dd, 1 H, J = 7.5, 5.0 Hz), 7.08-7.04 (m, 2 H), 6.39 
(s, 1 H), 5.53 (bs, 1 H), 4.10 (s, 3 H); 
13
C NMR (CDCl3, 75 MHz) 158.4, 157.2, 149.8, 148.7, 
147.4 (q, JCF = 35.3 Hz), 138.8, 137.7, 135.7, 128.7, 123.7, 121.6 (q, JCF = 273.8 Hz), 121.4, 
117.2, 115.0, 110.5, 72.0, 56.9; MS (EI); m/z 370 ([M+2]
+
, 65), 369 (70), 368 (M
+
, 100), 367 
(77), 260 (63), 108 (93); HRMS (EI) m/z calcd for C17H12ClF3N2O2 368.0539, found 368.0528. 
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APPENDIX A 
SELECTED 
1
H AND 
13
C NMR DATA FOR COMPOUNDS rac-24 and rac-36 
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